You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 289 No. 15, April 16, 2003 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Letters
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Contact me when this article is cited
 Related Content
 •Related articles
 •Similar articles in JAMA
 Topic Collections
 •Neurology
 •Cerebrovascular Disease
 •Stroke
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Reducing the Risk of Stroke

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: Dr Straus and colleagues1 stated that "the Antiplatelet Trialists' Collaboration [ATC]2 did not find that adding dipyridamole to aspirin resulted in significant benefit over the use of aspirin alone, but they noted that a single randomized trial found that the addition of extended-release dipyridamole to aspirin decreased the risk of death significantly." The ATC authors claimed that the results of this "single randomized trial" (ESPS-2),3 which demonstrated significant reduction in stroke risk, was inconsistent with preceding negative trials of dipyridamole plus aspirin for cardiovascular disease prevention and that its results may have arisen "largely or wholly by the play of chance."2

In fact, ESPS-2 was the only prospective, multicenter randomized trial that was adequately designed (2 x 2 factorial analysis) and adequately powered to determine the independent and additive efficacy of aspirin and (extended-release) dipyridamole. The number of patients and vascular events (including strokes) in ESPS-2 exceeded . . . [Full Text of this Article]

James M. Gebel, MD
Department of Neurology
University of Pittsburgh Medical Center
Pittsburgh, Pa

Louis R. Caplan, MD
Department of Neurology
Beth Israel Medical Center
Boston, Mass



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLES

Reducing the Risk of Stroke
Albert Fournier, Roxana Oprisiu, Michel Andrejak, Jean Michel Achard, and Leonardo Fernandez
JAMA. 2003;289(15):1927-1928.
EXTRACT | FULL TEXT  

Reducing the Risk of Stroke
Kamakshi Lakshminarayan and David C. Anderson
JAMA. 2003;289(15):1928.
EXTRACT | FULL TEXT  

Reducing the Risk of Stroke
Howard S. Kirshner
JAMA. 2003;289(15):1928.
EXTRACT | FULL TEXT  

Reducing the Risk of Stroke—Reply
Sharon E. Straus, Finlay A. McAlister, and Sumit R. Majumdar
JAMA. 2003;289(15):1929.
EXTRACT | FULL TEXT  

New Evidence for Stroke Prevention: Scientific Review
Sharon E. Straus, Sumit R. Majumdar, and Finlay A. McAlister
JAMA. 2002;288(11):1388-1395.
ABSTRACT | FULL TEXT  






HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2003 American Medical Association. All Rights Reserved.